Articles tagged with Opioid Receptors
Researchers at St. Jude Children's Research Hospital found that distinct GPCR ligands create different levels of activation by pushing the receptor through its activation steps at varying speeds. This affects the efficacy of agonists, with partial agonists getting stuck in kinetic traps and releasing G-proteins more slowly.
A team of scientists at the University of Florida has developed a new drug compound that selectively targets delta opioid receptors, providing pain relief without the dangerous side effects associated with opioids. The study's findings offer a promising approach to developing safer pain treatments, which could also be applied to treati...
A study published in Biological Psychiatry identified the Shisa7 gene as a key driver of heroin addiction. The research team used machine learning to analyze brain tissue from human opioid users and found that modulating this gene's expression influenced heroin-seeking behavior and cognitive flexibility.
Researchers developed a custom-designed compound that mimics natural cannabis molecules to alleviate chronic pain without psychoactive side effects. The modified synthetic cannabinoid compound showed promise as a nonaddictive pain reliever, offering prolonged relief and minimizing tolerance.
A group of nerve cells called POMC neurons are responsible for dessert cravings, releasing a feel-good opiate when mice eat sugar. This pathway is activated even before eating, and blocking it reduces sugar consumption in full animals.
A new microdosing approach using low doses of buprenorphine has been tested on patients with opioid use disorder, but most found it ineffective. The study, which included 126 participants, showed that only 34% were able to work up to a full dose of buprenorphine.
A new study reveals that delta opioid receptor agonist KNT-127 has a rapid and effective antidepressant effect with minimal side effects. The research highlights the molecular mechanisms underlying its action, including mTOR signaling pathways and Akt activation in the medial prefrontal cortex.
Researchers have discovered a new approach to treating fentanyl overdoses using naloxone methiodide, which blocks peripheral opioid receptors. This therapy reverses fentanyl-induced respiratory depression without causing withdrawal symptoms.
New research from the University of Pittsburgh found that opioids can suppress the immune system and reduce the effectiveness of immunotherapy for head and neck cancer. However, peripherally restricted OPRM1 antagonists (PAMORAs) may block opioid-induced immunosuppression and improve response rates to immune checkpoint inhibitor therapy.
Researchers found that increasing levels of the naturally occurring endocannabinoid 2-AG can counteract the rewarding properties of opioids, reducing addiction-like behaviors in mice. The study suggests a potential new therapeutic strategy to alleviate pain while minimizing opioid addiction risk.
A new study found that people with opioid or alcohol use disorder who take Ozempic or similar medications have a lower rate of opioid overdose and alcohol intoxication. The medication, which treats diabetes and weight-related conditions, may also alter the brain's reward-response pathways associated with substance use.
Researchers have discovered molecules capable of limiting the side effects of opioids by blocking the receptor responsible for their action. The scientists created even smaller molecules that retain the same properties, which could prove far more effective than current treatments in mitigating the harmful effects of opioids.
Researchers discovered that opioid receptors in the dorsal peduncular nucleus respond uniquely to opioids, blocking aversive feelings and leading to reward. This finding contributes to the pleasurable and addictive qualities of opioids.
Researchers at Mainz University have identified aniquinazolin B, a natural substance from the marine fungus Aspergillus nidulans, which stimulates opioid receptors and could potentially replace opioids in the long term. The compound shows promising results with fewer undesirable reactions compared to opioids.
Researchers have identified a novel compound that can reverse the lethal effects of opioid overdose when paired with naloxone, reducing withdrawal symptoms and extending protection. The discovery builds on new insights into opioid receptors and could combat the devastating fentanyl epidemic.
Researchers have identified a potential compound that enhances naloxone's effectiveness in reversing opioid overdoses by making it more potent and longer-lasting. The compound, dubbed compound 368, was found to improve naloxone's ability to counteract opioid overdoses in mice and enable reversal at lower doses.
Researchers at Rice University have identified genes critical for enteric nervous system development using zebrafish embryos. Opioid signaling pathways are required for the formation of nerves in the gut, contradicting previous assumptions about their role in pain perception and addiction.
A research team developed a fentanyl sensor that can detect the drug at ultralow levels, thanks to the use of carbon nanotubes, gold nanoparticles, and fentanyl antibodies. The sensor has a 91% success rate in distinguishing fentanyl from other opioids.
The study reveals how opioid receptors stabilize a state for effective signal transmission, making superagonists potent and dangerous. It also highlights the importance of understanding molecular interactions for drug development and developing safer medicines.
Researchers have found that LY2444296, a compound blocking the kappa opioid receptor, significantly reduced withdrawal symptoms and alcohol consumption in rats with alcohol dependence. The study suggests that blocking this receptor could lead to new treatment options for people experiencing alcohol use disorder.
Researchers developed injectable nanoparticles that release naloxone when triggered by blue light, potentially preventing opioid overdose deaths. The system showed effectiveness up to a month after injection and could be incorporated into a wearable device.
Researchers at University of Chicago identified a new pain relief pathway in the brain that produces powerful analgesic effects without tolerance or addictive risks. Targeting acetylcholine receptors, particularly alpha-7, offers a promising path to developing non-opioid painkillers.
A human antibody that targets carfentanil, fentanyl, and related opioids has shown promising results in reversing overdose effects in a preclinical study. The antibody, developed by Scripps Research, binds tightly to the potent opioid variants and reverses respiratory depression caused by carfentanil.
Researchers mapped the 3D structure of kappa opioid receptors, discovering how they change shape to bind to opioid drugs. This finding could lead to the development of next-generation pain relievers that target specific opioid receptors and minimize side effects.
A preclinical study found that the drug ADX106772 reduced oxycodone intake and relapse in animal models of opioid use disorder without disrupting other reward responses. The therapeutic was tested in rats trained to self-administer oxycodone and showed significant reduction in oxycodone intake for up to 12 hours.
Researchers at Indiana University have identified a new method to reverse the effects of fentanyl, which is 50 to 100 times stronger than morphine. Cannabidiol, or CBD, was found to behave as a negative allosteric modulator at the binding site, successfully reversing fentanyl effects in in vitro tests.
Researchers found that morphine interacts with toll-like receptor 4 to contribute to increased bone loss and pain. Blocking TLR4 prevents these effects, suggesting a new target for reducing opioid side effects.
A MU study found that providing educational information about naltrexone to healthcare professionals increases patient prescriptions for the drug. The study resulted in a 36% increase in patients leaving the facility with a prescription for naltrexone, suggesting better-informed decisions by healthcare professionals.
KNT-127 exhibits anti-stressing and anti-depressant effects in mice, improving social interaction and reducing stress-induced hormone levels. The agent suppresses neuronal inflammation and newborn death without affecting neurogenesis.
Researchers at Washington University School of Medicine have identified a potential mechanism behind hallucinations triggered by kappa opioid receptors, aiming to develop painkillers without these side effects. Targeting specific binding sites on the kappa receptor may relieve pain without inducing euphoria and addiction.
Researchers at UNIGE discovered that natural opioids cannot enter cells, whereas therapeutic opioids can, leading to differences in physiological responses. The study's findings could help develop safer medications with improved efficacy and reduced side effects.
Researchers have identified marijuana-derived compounds that can reverse fentanyl overdoses by reducing its binding to opioid receptors and boosting naloxone's effects. These compounds, derived from cannabidiol (CBD), demonstrate a synergistic effect when combined with naloxone.
Researchers at Texas A&M University School of Medicine have identified a specific brain circuit that characterizes how fentanyl affects the brain. Suppressing negative emotional states may increase a person's chance of overcoming opioid use disorder.
The study calls for easier access to naloxone, including over-the-counter distribution, to address the US opioid epidemic. With millions lacking access, health providers are urged to include naloxone in treatment programs and counsel patients' families on its use.
Researchers used cryoEM technology to solve detailed structures of the entire human opioid receptor family, providing a comprehensive framework for designing safer drugs. The study aims to overcome side effects and overdose deaths associated with current opioid pain relievers.
Researchers from the Chinese Academy of Sciences have discovered the molecular mechanisms by which opioids like fentanyl and morphine bind to the μ opioid receptor. The study reveals that fentanyl binds to an extra pocket outside the receptor, leading to its higher potency compared to morphine.
Scientists at FAU have discovered new substances that activate adrenaline receptors instead of opioid receptors, providing effective pain relief without respiratory depression or addiction. The findings are a milestone in the development of non-opioid pain medication.
A new study at the Turku PET Centre discovered that shorter daylight hours increase opioid receptor levels in brown fat of rats. This complements previous findings on day length modulating opioid receptor levels in brain emotional circuits.
A study reveals the oligomeric molecular structure of MOR-Gal1R complex, involved in opioids' analgesic and addictive effects. The complex forms different structures, such as homodimers and heterotetramers, which affect signal pathways.
Researchers at Scripps Research Institute have synthesized GB18, a psychotropic compound found in the bark of the Galbulimima belgraveana tree. The compound binds to opioid receptors in the brain, potentially offering new hope for treating depression and anxiety. Further studies are needed to adapt it for human use.
A Rutgers University study found that expanding prison opioid treatment programs could reduce the risk of overdose and death among ex-inmates. The researchers suggest that further education on post-release opioid risks is necessary to increase participation in these programs.
A University of South Florida study suggests targeting kappa-opioid receptors may alleviate working memory deficits and improve executive function in individuals with severe alcohol use disorder. A compound blocking these receptors alleviated working memory deficits and restored normal executive function.
Researchers found that blood pressure medications increase the effect of opioids in the brain, fine-tuning a specific circuit and reducing addiction risk. This discovery suggests a new strategy to boost opioid signaling with minimal dependence on pain treatment.
A Salk Institute team has uncovered a neural network in the brain that connects breathing rhythm with feelings of pain and fear. This discovery could lead to the development of an analgesic that prevents opioid-induced respiratory depression, a major cause of overdose deaths.
Researchers have identified a new pathway for opioid-induced reward in the brain, paving the way for creating safer opioids. By altering the opioid peptide receptor MOPR, pharmaceutical companies can potentially create drugs that bypass the brain's reward system.
A recent study published in Frontiers in Immunology found that opioids can control gut immune responses, reduce colonic inflammation, and even promote the growth of regulatory T cells. The findings suggest that KNT-127 could be a promising therapeutic option for inflammatory bowel disease.
Scientists challenge existing thinking on opioid tolerance and respiratory depression, proposing a new balanced approach to developing safer analgesics. They found that arrestin-3 engagement limits tolerance development but does not exacerbate respiratory depression.
Scientists identified conolidine's interaction with ACKR3/CXCR7, a novel opioid receptor, to increase analgesic activity and block pain relief-dampening effects. A synthetic analogue, RTI-5152-12, was developed to enhance pharmacological properties.
A new study uses CLARITY technique to visualize opioid receptor distribution across the entire brain in 3D images, revealing previously unknown areas susceptible to opioids. The researchers identified extensive tracts related to pain and reward, as well as many neural tracts not previously known to express opioid receptors.
Researchers developed LIH383, a novel molecule targeting ACKR3, which modulates natural painkilling and antidepressant properties by reducing opioid peptide levels. This discovery offers an alternative therapeutic strategy for chronic pain, stress, anxiety, and depression, as well as cancer treatment.
A new study finds that targeting the delta opioid receptor can provide sustained relief from chronic inflammatory pain. Researchers used nanoparticles to deliver a painkiller to the receptors, avoiding side effects and improving effectiveness.
A study by Medical University of South Carolina researchers identified a specific brain region and system that can be manipulated to decrease binge drinking. The kappa opioid-receptor system plays a crucial role in driving binge and compulsive alcohol use, as well as contributing to stress and unease during withdrawal.
Researchers have developed highly selective ligands to label opioid receptors, shedding light on their behavior in living cells. The study reveals that most opioid receptors exist as individual entities, but a small proportion forms pairs, which may contribute to the receptor's function.
A Scripps Research study found that blocking the kappa opioid receptor while on a restricted-calorie diet resulted in significant weight reductions. Blocking this receptor may be a potential treatment approach for obesity.
The Wistar Institute has been awarded $12M to investigate the impact of opioid use disorder on immune recovery in HIV-infected people. The study aims to find the best pharmacologic strategy for managing opioid use disease in HIV-infected individuals starting antiretroviral therapy.
Scientists identified a receptor, GPR139, in nematodes that decreases opioid sensitivity and withdrawal effects. The discovery could pave the way for developing new treatments with improved safety and efficacy.
Researchers identified a link between the kappa opioid receptor and naltrexone's effectiveness in reducing craving and consumption in heavy drinkers. The study suggests that individuals with more kappa opioid receptors may not respond to naltrexone treatment, highlighting the need for personalized treatment approaches.
Researchers at Johns Hopkins clarify ketamine's antidepressant properties, stating it binds to NMDA receptors rather than opioid receptors. This mechanism allows ketamine to turn off the master control switch mTOR, enabling its therapeutic effects. The FDA has approved ketamine as a nasal spray for depression treatment.
Research suggests that blocking opioid receptors can reverse the increase in sugar consumption caused by hormone therapy. The study found that estradiol treatment increased sugar intake in rats, but blocking opioid receptors with naltrexone reversed this effect.
Researchers at WashU Medicine developed a pain killer that blocks kappa opioid receptors to restore motivation in rodents. The compound dampens the negative emotions associated with pain without causing euphoria, offering a potential approach to less addictive pain treatment.